Breakout Ventures

The journey of bringing bio-based technologies from the lab to the market is anything but easy, and having a trusted guide can make all the difference.  𝐖𝐞 𝐚𝐫𝐞 𝐭𝐡𝐫𝐢𝐥𝐥𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐞 𝐚𝐝𝐝𝐢𝐭𝐢𝐨𝐧 𝐨𝐟 𝐟𝐢𝐯𝐞 𝐧𝐞𝐰 𝐯𝐞𝐧𝐭𝐮𝐫𝐞 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬 𝐭𝐨 𝐨𝐮𝐫 𝐭𝐞𝐚𝐦! These industry experts will support Breakout, our portfolio, and our broader ecosystem — from diligencing investment opportunities to commercializing new tech. 𝐏𝐥𝐞𝐚𝐬𝐞 𝐣𝐨𝐢𝐧 𝐮𝐬 𝐢𝐧 𝐰𝐞𝐥𝐜𝐨𝐦𝐢𝐧𝐠: ✨ Sridhar Iyengar, PhD: Founder and Chief Strategy Officer of Elemental Machines ✨ Coco Krumme, PhD: Founder of Leeward Co ✨ Rebecca Nugent, PhD: VP of HTP Operations at Tessera Therapeutics ✨ Walter Solomon: Board Director and Advisor ✨ Ilan Zipkin, PhD: Founder and CEO of Supercede Therapeutics, Inc. Breakout Ventures is built on the theory that creative bioscience founders need more than just capital to take on the world's biggest challenges in human health and sustainability. Thank you to our venture partners, advisors, and community members for helping us build a bio-based future! 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/gp4SADTe

TIME’s 2024 Best Inventions issue spotlights the boldest breakthroughs shaping our world. High on this year's list: WNDR Alpine's snowboard made from Checkerspot's microalgae technology. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞: 🥇 Each year, TIME highlights 200 of the the most transformative products and ideas reshaping fields like health care, artificial intelligence, and green energy. 🏂 Wonder Alpine—made from Checkerspot's AlgalTech™—won a top spot with their sustainable Alpine Shepherd snowboard. 🦠 Specifically engineered to enhance the board's “damping” effect to reduce vibration, the microalgae-produced material shows how biomaterials can meet rigorous performance needs 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐬𝐭𝐨𝐫𝐲: https://lnkd.in/ghiyzHqa

Heading to the SITC Annual Meeting this week? Be sure to check out the 𝒇𝒐𝒖𝒓 presentations featuring data from CellChorus' single-cell analysis technology. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞: 🦠 Each year, the Society for Immunotherapy of Cancer (SITC) gathers researchers and partners dedicated to improving cancer patient outcomes through advancing the science and application of cancer immunotherapy. 🔬 CellChorus, a Breakout Ventures portfolio company, has designed a Time-lapse Imaging Microscopy in Nanowell Grids™ (TIMING™) platform that quantifies spatiotemporal behaviors of thousands of immune cells to identify drug candidates to move into clinical trials and understand cellular response at the most precise level. 📰 Abstracts and their presenters include: • 11/8: Artificial Intelligence-Based Dynamic Single-Cell Imaging Reveals Enhanced Migration and Immune Synapse Formation by IDP-023, an Allogeneic g-NK Cell Product (Matthew C., Indapta Therapeutics) • 11/8: Single-cell functional analysis accelerates design, translational research, clinical development, and process development of immunotherapies (Rebecca Berdeaux, CellChorus) • 11/8: TIMING™-based functional single cell analysis reveals enhanced function of CAR T cells engineered using microfluidic vortex shedding (Rebecca Berdeaux, CellChorus, featuring research from Indee Labs) • 11/9: Single-cell proliferation assay enables rapid and quantitative donor screening (Hannah W., CellChorus) 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 CellChorus 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/deEXNmRR #SITC #SITC2024

Breakout portfolio company Incendia Therapeutics is teaming up with DELFI Diagnostics to evaluate treatment response and disease progression in their Phase I clinical trial on reprogramming the tumor microenvironment. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞 💊 Designed around data from spatial characterization, multi-omics integration, and extensive preclinical testing, Incendia Therapeutics' technology reprograms the tumor microenvironment to treat advanced solid tumors. 🔍 This new partnership is intended to improve precision medicine by enabling Incendia Therapeutics to gather critical early insights into the effectiveness of treatment with DELFI Diagnostics' cutting-edge cfDNA-based technology. 🔬 The DELFI-TF assay requires less than 1 mL of plasma—far less than other cfDNA assays—allowing more efficient use of blood samples in early clinical studies with high sample demands. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/dzSN4Nb8

Innovative biotech is developing around the world - 𝘴𝘰 𝘸𝘩𝘺 𝘴𝘩𝘰𝘶𝘭𝘥 𝘧𝘶𝘯𝘥𝘪𝘯𝘨 𝘣𝘦 𝘭𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘳𝘦𝘨𝘪𝘰𝘯? Learn from VCs, industry leaders, and academics how to get the capital you need, no matter where you're based. 𝐄𝐯𝐞𝐧𝐭 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞: 🤝 The Chicago BioCapital Summit gathers together all the people who make biotech happen—founders, funders, researchers, partners, and more—to form connections and share insights 💡 From funding strategies to understanding local strengths, the panel "Attracting Capital to Emerging Biotech Hubs" on Thursday, November 7ths will teach you how to create the right conditions to attract capital and foster regional biotech ecosystems. 🎤 Moderated by Julia Monfrini Peev (PACE Healthcare Capital), speakers include our own Dana Watt, PhD (Breakout Ventures), Tim Walbert (Amgen, fmr. Horizon), Michal Preminger (Johnson & Johnson Innovative Medicine), Stephen Squinto (J.P. Morgan), and Martin Burke (University of Illinois Urbana-Champaign) Thank you to the #CBCSummit2024 team for inviting us to speak at such at great event! 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐂𝐡𝐢𝐜𝐚𝐠𝐨 𝐁𝐢𝐨𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐒𝐮𝐦𝐦𝐢𝐭 𝐚𝐧𝐝 𝐫𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐭𝐨𝐝𝐚𝐲: https://lnkd.in/gXziGSA4

Cell therapy news! CAR27 NK cells with CD28-based costimulation resulted in significantly better serial killing and survival in animals, thanks to CellChorus' TIMING™ platform. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞: 👩🔬 CellChorus’ TIMING™ platform was spotlighted in Cancer Discovery for describing the design of a novel CAR27 NK therapy with CD28 costimulation for patients with CD70+ hematologic malignancies and solid cancers. 🔬 TIMING’s multi-dimensional, time-lapse analysis of single cells enables unmatched profiling of cellular function and therapeutic potential. TIMING™ quantified the difference in serial killing between the CARs harboring varying intracellular domains to show that three times more NK cells were able to kill more than one target cancer cell when the best intracellular domain was used. 🤝 These findings are thanks to collaborations with researchers from the University of Texas MD Anderson Cancer Center, the University of Houston, the Technical University of Munich, Baylor College of Medicine, and the University of Nebraska at Omaha Medical Center. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/dvcUJzrA 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 Springer Nature 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/ekNK9iSD 𝐏𝐒 - Be sure to check out the Supplementary Videos to see the cells in action: https://lnkd.in/dPG6SqH3

We had a great time at RAISE Global last week, where our Managing Partner Julia Moore shared how we identify and support early-stage startups at the intersection of technology, biology, and chemistry. 𝐐𝐮𝐢𝐳 𝐓𝐢𝐦𝐞! What do these three companies—Twelve, Cytovale, and NOETIK—have in common? 𝐀: N of 1 technologies with power law potential  𝐁: An intersection of AI, biology, and chemistry never seen before 𝐂: Founder-led startups Breakout Ventures partnered with early 𝐃: All of the above ... If you guessed D... congratulations! And you'd be right with this answer for all of the Breakout Ventures portfolio companies. We invest in early stage (Seed through Series A) startups solving the world's most urgent challenges in human and climate health. We lead and join syndicates across the tech+bio+chem ecosystem, sitting on the boards of ~90% of our portfolio companies to help intrepid founders turn their technology into scaleable solutions. Thank you again to the team at RAISE Global for selecting Breakout Ventures to speak at this incredible event. We're looking forward to next year already.

Every second counts for curing sepsis—the last thing you want is to wait 8 hours for a diagnosis. Cytovale's diagnostic, which gives doctors the answer they need in an hour, has expanded into three health centers. 𝐍𝐞𝐰𝐬 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞: 🚑 Cytovale's IntelliSep® helps reduced sepsis mortality rates 30%, cutting hospital stays by over a day and costs by nearly $1,500 per patient. 🏥 Freeing up 23-30 hours of nursing time monthly, the diagnostic is now triaging patients across Franciscan Missionaries of Our Lady Health System, expanding to St. Dominic Hospital in Jackson, Mississippi, St. Francis Medical Center in Monroe, Louisiana, and Our Lady of Lourdes Regional Medical Center in Acadiana Louisiana. 🩺 Per E.J. Kuiper, President and CEO of Franciscan Missionaries of Our Lady Health System, "This groundbreaking advancement underscores our commitment to pioneering innovative healthcare solutions and improving patient outcomes." 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐫𝐞𝐥𝐞𝐚𝐬𝐞: https://lnkd.in/guAp2NUH

Thank you Breakout Ventures for the inspiring #Magnify event yesterday in San Francisco! Great panel discussion on the challenges of drug development. Avenue Biosciences #biologics #therapeuticproteins #drugdevelopment

Happy to report that the Three Body Problem is fiction, not a documentary. Learning about all the scientific breakthroughs at the Breakout Ventures AGM yesterday that are decreasing sepsis deaths by 30%, turning air into jet fuel, utilizing AI biotech cancer therapeutics and more filled me with hope for the inventions molding the future of humanity. This is VC innovation at its best! Thanks to Lindy Morris Fishburne, Julia Moore, and the entire BV team for the wonderful work you are doing! #amazingventurecapital